Gut Bacteria Shifts in Chronic Heart Failure: New GC-MS Data Reveals the Damage

Chronic heart failure already claims enormous tolls in mortality and hospitalization worldwide, but a study published in the Russian journal Therapy now adds a precise microbial dimension to that burden. Researchers at RUDN University in Moscow used gas chromatography-mass spectrometry to quantify absolute changes in gut bacterial populations among 25 hospitalized CHF patients, compared against 23 healthy volunteers. The findings reinforce the pathogenic role of the gut-heart axis in cardiovascular disease and offer the kind of species-level resolution that relative sequencing methods have struggled to provide.

Opportunistic Pathogens Rise While SCFA Producers Fall

The core result is a double-edged shift. On one side, CHF patients showed statistically significant increases in several opportunistic, proinflammatory microorganisms: Campylobacter mucosalis, Candida spp., Alcaligenes spp. or Klebsiella spp., and Clostridium difficile (all p < 0.05). Counts of Cytomegalovirus HHV-5 were also elevated. On the other side, bacteria that produce short-chain fatty acids (SCFAs), molecules known to protect intestinal barrier integrity and dampen systemic inflammation, were significantly depleted. The affected species included Clostridium ramosum, Propionibacterium jensenii, Blautia coccoides, Bacteroides fragilis, and Eubacterium spp. (all p < 0.05).

SCFAs such as butyrate are not merely metabolic by-products. Butyrate, for instance, has demonstrated inotropic and cardioprotective properties in cardiac tissue, and its depletion is consistent with microbial profiles linked to worsened heart failure conditions, including reduced left ventricular ejection fraction. The simultaneous loss of Bacteroides fragilis, a species with documented roles in modulating immune responses, compounds the inflammatory pressure on the failing heart.

Why These Microbiota Shifts Matter for CHF Severity

The RUDN team did not stop at cataloguing differences. They identified associations between specific microbial counts and the clinical and functional parameters measured for each patient. These parameters included left ventricular ejection fraction (LVEF), bioimpedance vector analysis, liver fibroscanning, blood biochemistry, nutritional status (assessed via the MNA tool), and sarcopenia screening (SARC-F and MSRA-7 questionnaires).

The patient cohort was clinically diverse: 60% had low LVEF (n=15), 16% had moderately reduced LVEF (n=4), and 24% had preserved LVEF (n=6). The mean age was 75 years (standard deviation 9.4 years), and 18 of 25 patients were male. That microbial disruptions mapped onto functional measures across all three LVEF categories suggests the gut-heart relationship operates regardless of ejection fraction subtype, not only in the most severe cases.

The rise of C. difficile in particular carries practical clinical weight. Hospitalized heart failure patients already face elevated risk from bacterial co-infections, and gut dysbiosis appears to create permissive conditions for opportunistic colonization at precisely the moment cardiac reserve is most compromised.

GC-MS Fills a Gap Left by Sequencing-Based Studies

Most prior research on gut microbiota in CHF has relied on relative abundance data from next-generation 16S rRNA gene sequencing. A representative example is a 16S rRNA gene sequencing study of severe CHF patients that identified compositional differences between patients and controls but could not determine whether individual species were genuinely more or less numerous in absolute terms.

GC-MS-based profiling sidesteps this limitation by measuring actual microbial mass, expressed as absolute counts rather than proportions. A species that appears to decline in relative terms might actually be stable in absolute terms if another organism expands. By fixing absolute numbers, the RUDN approach rules out that confound. This methodological clarity is central to the paper's contribution: the decreases in SCFA producers and increases in opportunistic organisms represent real shifts in microbial load, not compositional artifacts of a changing denominator.

The study enrolled 25 CHF patients hospitalized at a multidisciplinary facility and compared them with 23 healthy controls, applying the same GC-MS methodology to both groups. Additional clinical characterization, including liver fibroscanning and nutritional and sarcopenia assessments, enriched the correlation analyses beyond what purely microbiome-focused studies typically attempt.

Sarcopenia, Nutrition, and the Wider Systemic Picture

The inclusion of sarcopenia screening is noteworthy. CHF and sarcopenia frequently co-occur in older patients, and the gut microbiome has emerged as a plausible mechanistic link between the two conditions. SCFA-producing bacteria support skeletal muscle protein synthesis partly through mTOR signaling pathways, meaning that the depletion of these organisms in CHF patients could contribute directly to muscle wasting alongside cardiac deterioration.

Nutritional status assessment (MNA) in the same patients provides an additional layer. Malnutrition in CHF is both common and prognostically important, and gut dysbiosis impairs nutrient absorption in ways that standard dietary surveys may not capture. The associations between microbial counts and nutritional scores in this dataset open a line of inquiry into whether correcting specific bacterial deficits could improve nutritional outcomes independent of dietary intervention.

Toward Microbial Markers and Targeted Microbiotherapy

The authors frame their results as a step toward two practical goals: identifying microbial markers that reflect dysbiosis severity, and developing targeted microbiotherapy for CHF. The specific species identified as depleted or enriched provide candidate targets for intervention design.

Probiotics formulated around Blautia coccoides or butyrate-producing organisms, or selective antimicrobials to reduce C. difficile burden, are conceivable directions. The GutHeart clinical trial, a Phase II randomized study testing antibiotics and probiotics in stable heart failure patients, represents the kind of translational work that findings like these are intended to inform.

What this study adds is specificity: named organisms, absolute counts, and correlations with functional clinical parameters. That level of resolution is what the field needs to move from observational associations to mechanistic targets. The RUDN team's GC-MS approach offers a replicable template, and a larger multicenter cohort using the same methodology would substantially strengthen the case for any individual species as a viable therapeutic entry point.